Related Experiment Videos
The lupus syndrome induced by hydralazine: a common complication with low dose treatment
Insights
The lupus syndrome, a side effect of hydralazine medication for hypertension, occurred in 6.7% of patients after three years. This risk was higher with increased dosage and in women.
Area of Science:
- Pharmacology
- Clinical Medicine
- Immunology
Background:
- Hydralazine is an effective antihypertensive medication.
- A known risk of hydralazine is the induction of a lupus-like syndrome.
- Current recommendations restrict hydralazine dosage due to this risk.
Purpose of the Study:
- To determine the true incidence of hydralazine-induced lupus syndrome.
- To analyze the relationship between hydralazine dosage, duration, and syndrome development.
Main Methods:
- A longitudinal study of 281 patients initiating hydralazine for hypertension.
- Life table analysis was used to examine treatment duration and maximum dosage.
- Patient data were collected over a 51-month period.
Main Results:
- The three-year incidence of hydralazine-induced lupus syndrome was 6.7%.
- Incidence demonstrated a dose-dependent relationship: 0% at 50 mg, 5.4% at 100 mg, and 10.4% at 200 mg daily.
- Women exhibited a higher incidence (11.6%) compared to men (2.8%), with a 19.4% three-year incidence in women taking 200 mg daily.
Conclusions:
- The incidence of hydralazine-induced lupus syndrome remains unacceptably high, even at recommended dosages (≤200 mg daily).
- The risk is significantly influenced by dosage and patient sex.
- Further strategies are needed to mitigate this adverse drug reaction.
Abstract:
The true incidence of the lupus syndrome induced by hydralazine was determined in a longitudinal study of 281 patients consecutively starting hydralazine for hypertension over a 51 month period. Data on the duration of treatment and the maximum dose achieved were examined using life table analysis. After three years' treatment with hydralazine the incidence of the lupus syndrome was 6.7% (95% confidence limits 3.2-10.2%). The incidence was dose dependent, with no cases recorded in patients taking 50 mg daily and incidences of 5.4% with 100 mg daily and of 10.4% with 200 mg daily. The incidence was higher in women (11.6%) than in men (2.8%). In women taking 200 mg daily the three year incidence was 19.4%. Hydralazine is an effective antihypertensive drug that has come to be used in restricted dosage (not more than 200 mg daily) because of its risk of inducing the lupus syndrome. This study shows that the true incidence of the syndrome is still unacceptably high even when the drug is prescribed according to current recommendations.